Context: The clinical course of secondary hyperparathyroidism (sHPT) in patients on hemodialysis is not well described, and the effect of the calcimimetic cinacalcet on disease progression is uncertain.
Objective: Our objective was to describe 1) the clinical course of sHPT in patients treated with phosphate binders and/or vitamin D sterols and 2) the impact of cinacalcet on the occurrence of severe unremitting HPT, defined by the persistence of markedly elevated PTH concentrations together with hypercalcemia or parathyroidectomy (PTX).
Design And Setting: This was a randomized, double-blind, placebo-controlled, global, multicenter clinical trial.
Patients: Of 5755 patients screened with moderate to severe sHPT, 3883 patients on hemodialysis were included in the trial.
Main Outcome Measures: Outcomes included PTX; severe, unremitting HPT; and use of commercial cinacalcet (a protocol violation).
Intervention: Intervention was cinacalcet (30-180 mg daily) or placebo for up to 64 months.
Results: In the 1935 patients randomized to placebo, 278 patients (14%) underwent PTX (median PTH 1872 pg/mL within the previous 12 weeks from surgery). Age, sex, geographic region, co-morbidity, calcium-containing phosphate binder use, and baseline serum calcium, phosphorus, and PTH concentrations were associated with PTX. Commercial cinacalcet was started in 443 (23%) patients (median PTH 1108 pg/mL before treatment began). Severe unremitting HPT developed in 470 patients (24%). In a multivariable Cox model, the relative hazard (comparing patients randomized to cinacalcet versus placebo) of severe unremitting HPT was 0.31 (95% confidence interval = 0.26-0.37). The relative hazard differed little when adjusted by baseline clinical characteristics.
Conclusions: Severe unremitting HPT develops frequently in patients on hemodialysis despite conventional therapy, and cinacalcet substantially reduces its occurrence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1210/jc.2013-2975 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
RNA Binding Protein Dysfunction Links Smoldering/Slowly Expanding Lesions to Neurodegeneration in Multiple Sclerosis.
Ann Neurol
February 2025
Office of the Saskatchewan Multiple Sclerosis Clinical Research Chair, University of Saskatchewan, Saskatoon, SK, Canada.
Article Synopsis
- Research highlights that despite improvements in multiple sclerosis (MS) treatments, neurodegeneration remains a key factor contributing to disability and disease progression, particularly through the dysfunction of the RNA binding protein hnRNP A1 and the presence of smoldering/slowly expanding lesions (SELs).
- The study utilized immunohistochemistry to compare hnRNP A1 pathology in brains of healthy individuals and those with MS, finding a significant correlation between high hnRNP A1 dysfunction and increased neurodegeneration markers in progressive MS cases.
- Findings suggest that hnRNP A1 dysfunction not only plays a role in neurodegeneration but may also be worsened by SELs; notably, some neurons were discovered to be injured but not
Background: Metabolic substrate utilization in HFpEF (heart failure with preserved ejection fraction), the leading cause of heart failure worldwide, is pivotal to syndrome pathogenesis and yet remains ill defined. Under resting conditions, oxidation of free fatty acids (FFA) is the predominant energy source of the heart, supporting its unremitting contractile activity. In the context of disease-related stress, however, a shift toward greater reliance on glucose occurs.
View Article and Find Full Text PDFA surgical approach to complex regional pain syndrome with neurogenic thoracic outlet syndrome in a reoperation patient.
Pain Manag
October 2024
Vascular Institute of the Rockies (VIR), 4105 E Florida Ave., Denver, CO 80222, USA.
Article Synopsis
- Thoracic outlet syndrome (TOS) involves compression of nerves and blood vessels in the upper body, while complex regional pain syndrome (CRPS) is a chronic pain disorder without a clear physical cause.
- A 22-year-old woman experienced both TOS and CRPS following an arm injury, leading to severe pain that persisted for a decade.
- After multiple surgeries, her symptoms significantly improved during the third operation, where doctors focused on nerve relief and reducing scar tissue.
Repetitive transcranial magnetic stimulation in new daily persistent headache patients: a single arm open label study.
J Headache Pain
September 2024
Department of Psychiatry, Apex Trauma Centre, SGPGIMS, Lucknow, India.
Article Synopsis
- - The study investigated the effects of repetitive transcranial magnetic stimulation (rTMS) on patients with new daily persistent headache (NDPH), focusing on reducing headache frequency and severity as well as alleviating anxiety and depression symptoms.
- - Fifty participants (average age 35) underwent rTMS treatment over three consecutive days, with results showing that 70% experienced at least a 50% reduction in headache severity, and 76% had significant improvement in headache impact scores after four weeks.
- - The study found the most significant benefits for NDPH patients who also had chronic migraines, while a small number of participants reported discomfort with the rTMS treatment.
Percutaneous cervical cordotomy for managing refractory pain in a patient with a Pancoast tumor: A case report.
World J Clin Cases
July 2024
Department of Anesthesiology, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Background: According to the World Health Organization analgesic ladder, cancer-related pain generally begins with pharmacotherapy in a stepwise approach. Nevertheless, some patients continue to experience poorly controlled pain despite medications, particularly when considering adverse effects and self-care quality. Percutaneous cervical cordotomy is an alternative interventional procedure for unremitting unilateral intractable cancer-related pain.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!